Steven Isaacman

13853-steven-isaacman

Nanometics LLC

2014-2015

Affiliations

New York University

Technologies

Therapeutic

Indication

Basic Research

Clinical Research

Clinical Trials

Drug Discovery

Oncology

Orphan Diseases

We are developing an enzyme inhibitor with pico-­‐molar binding affinity and minimal toxicity as a once daily, oral therapeutic for the treatment of triple-­‐negative breast cancer.

Newsletter Signup

Corporate Supporters

Community Service Providers